Maiwei Biotech said its holding subsidiary Maiwei Vision has entered a strategic
collaboration with ophthalmic small-molecule developer Weimou Biotech. The firms
will undertake comprehensive, in-depth cooperation targeting unmet clinical
needs in ocular inflammation and ocular immunity.